# Alleviation of nonalcoholic steatohepatitis induced by tetracycline in rats by Coffee Arabica extract through autophagy signals (mTOR/LC3-B)

**Authors:** Merehan Alaa-ElDin Mohamed, Said S. Moselhy, Shaimaa Rihan, Mustafa M. M. Elbakry

PMC · DOI: 10.1038/s41598-026-43605-6 · 2026-03-27

## TL;DR

Coffee Arabica extract may help protect against liver damage caused by a specific type of liver disease in rats by boosting a cellular recycling process.

## Contribution

This study shows that Coffee Arabica extract can alleviate tetracycline-induced NASH in rats through modulation of autophagy signals.

## Key findings

- Coffee Arabica methanolic extract (CAME) reversed abnormal mTOR and LC3-B levels caused by tetracycline in rats.
- Electron microscopy showed liver tissue improvement in rats treated with CAME after tetracycline exposure.
- Chlorogenic acid in CAME showed favorable binding energy to mTOR, suggesting a potential mechanism of action.

## Abstract

The autophagy mechanism is a key point for liver protection against nonalcoholic steatohepatitis (NASH). By specifically selecting Coffea arabica, this study leverages its high concentration of chlorogenic acid to modulate autophagy, a critical cellular recycling process that is typically suppressed during the development of NASH-related liver damage. We investigated the impact of Coffea Arabica methanolic extract (CAME) on autophagy-related markers (mTOR and LC3-B) mediated abrogation of tetracycline (TET) induced NASH in rats. Sixty male albino rats weighing 150 ± 10 g were equally divided into six groups: group 1 (control) received a chow diet; group 2 (NASH) received TET orally (1 g/kg bw) for 8 days; group 3 (CAME) received Coffea Arabica methanolic extract (CAME) orally (100 mg/kg bw) for 28 days; group 4 (treatment) received TET then CAME treatment for 28 days; group 5 (preventive) received CAME (100 mg/kg) for 28 days then TET orally (1 g/kg) for 8 days; and group 6 (protective) received both TET and CAME orally for 8 days. ELISA technique was used to measure mTOR and LC3-B content in liver tissue homogenate. Moreover, transmission electron microscope analysis carried out to detect pathological alterations in liver tissue. Also, molecular docking analysis was done. Coffea Arabica methanolic extract analysis by GC/MS revealed that CAME contained the highest percentage of chlorogenic acid (12.7963%). The biochemical data obtained pointed out that the mTOR level was significantly increased (~71.62%) while LC3-B decreased (~28.08%) in the NASH group compared with control. Administration of CAME abrogated these abnormalities. Liver examination by electron microscope indicated improvement abnormalities caused by TET in treatment with CAME. Docking study showed that chlorogenic acid has binding energy  − 7.554 favorable to mTOR than ATP-γS. We concluded that CAME stimulated a protective mechanism against NASH via LC3B and mTOR modulation which should attract further research to confirm our results and fully understand its mechanism of induction.

## Linked entities

- **Proteins:** MTOR (mechanistic target of rapamycin kinase), MAP1LC3B (microtubule associated protein 1 light chain 3 beta)
- **Chemicals:** chlorogenic acid (PubChem CID 1794427), tetracycline (PubChem CID 54675776)
- **Diseases:** nonalcoholic steatohepatitis (MONDO:0007027), NASH (MONDO:0007027)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, Anxa3 (annexin A3) [NCBI Gene 25291] {aka Anx3, LC3, LRRGT00047}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, Becn1 (beclin 1, autophagy related) [NCBI Gene 56208] {aka Atg6}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Sqstm1 (sequestosome 1) [NCBI Gene 113894] {aka Osi, ZIP, ZIP3}, Map1lc3b (microtubule-associated protein 1 light chain 3 beta) [NCBI Gene 67443] {aka 1010001C15Rik, Atg8, LC3b, MAP1A/MAP1B, Map1lc3}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Prmt1 (protein arginine methyltransferase 1) [NCBI Gene 60421] {aka Hrmt1l2}, MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631] {aka ATG8F, LC3B, MAP1A/1BLC3, MAP1LC3B-a}, Map1lc3b (microtubule-associated protein 1 light chain 3 beta) [NCBI Gene 64862] {aka LC3B, Map1lc3, Mpl3, zbs559}, Rps6kb1 (ribosomal protein S6 kinase B1) [NCBI Gene 72508] {aka 2610318I15Rik, P70S6K1, S6K, S6K-beta-1, S6K1, p70 S6K-alpha}, Becn1 (beclin 1) [NCBI Gene 114558] {aka Beclin1}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, Map1lc3a (microtubule-associated protein 1 light chain 3 alpha) [NCBI Gene 66734] {aka 1010001H21Rik, 4922501H04Rik, LC3, LC3a}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}
- **Diseases:** liver damage (MESH:D056486), cirrhosis (MESH:D005355), weight loss (MESH:D015431), liver injury (MESH:D017093), liver disease (MESH:D008107), fatty liver (MESH:D005234), inflammation (MESH:D007249), infections (MESH:D007239), insulin (MESH:D007333), obese (MESH:D009765), NAFLD (MESH:D065626), testicular damage (MESH:D013733), atherosclerosis (MESH:D050197)
- **Chemicals:** epoxy (MESH:D004853), Lactose (MESH:D007785), Lys (MESH:D008239), caffeine (MESH:D002110), Mg (MESH:D008274), 1,4-dimethylbenzene] (MESH:C031286), Leu (MESH:D007930), trimethyl chlorosilane (MESH:C039293), methanol (MESH:D000432), helium (MESH:D006371), ATP (MESH:D000255), polyphenol (MESH:D059808), metal (MESH:D008670), TMS (MESH:D013932), TET (MESH:D013752), glutaraldehyde (MESH:D005976), Asp (MESH:D001224), CGA (MESH:C554042), phosphatidylethanolamine (MESH:C483858), ATP-gammaS (MESH:C022571), nicotinate (MESH:D009525), alkaloids (MESH:D000470), flavonoid (MESH:D005419), quercetin (MESH:D011794), osmium tetroxide (MESH:D009993), Gly (MESH:D005998), Chlorogenic acid (MESH:D002726), water (MESH:D014867), 3-(4-Morpholin-4-ylpyrido[3',2':4,5]furo[3,2-D]pyrimidin-2-yl)phenol (-), cholesterol (MESH:D002784), bergamot (MESH:C068336), lead acetate (MESH:C008261), thiopental (MESH:D013874), curcumin (MESH:D003474), hydrogen (MESH:D006859), Mannobiose (MESH:C014647), Sitosterol (MESH:C025473), Met (MESH:D008715), fatty acids (MESH:D005227), ethanol (MESH:D000431), lactone (MESH:D007783), N, O-Bis(trimethylsilyl)trifluoroacetamide (MESH:C103255), PI-103 (MESH:C522973), resveratrol (MESH:D000077185), uranyl acetate (MESH:C005460), fat (MESH:D005223), lipid (MESH:D008055), PP242 (MESH:C572919), 9-(6-aminopyridin-3-yl)-1-[3 (trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1 H)-one (MESH:C558529), Trp (MESH:D014364), triglycerides (MESH:D014280)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Coffea arabica (arabica coffee, species) [taxon 13443], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13036025/full.md

---
Source: https://tomesphere.com/paper/PMC13036025